Login to Your Account

Dievini Hopp Shows Mettle for EU Biotech Investing

By Cormac Sheridan
Staff Writer

Wednesday, September 19, 2012
The €80 million (US$104.9 million) investment by dievini Hopp BioTech Holding GmbH & Co. KG in Tuebingen, Germany-based CureVac GmbH is not only its single biggest bet to date, but also a clear point of differentiation between itself and most other private investors in European biotechnology. (See story this issue.)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription